Various mpox recombinant subunits induce broadly reactive antibodies against orthopoxvirus in mice

Longitudinal viral shedding and antibody response characteristics of men with acute infection of monkeypox virus: a prospective cohort study

“…Researchers are developing mRNA and sub-unit vaccines based on different sets of antigens 52 – 59 . Several surface proteins of MPXV, including M1R, E8L, H3L, A29L on the IMV, A35R, and B6R proteins on the EEV, have been found to be potential vaccine targets for MPVX 29 .…”

“…The MPXV surface proteins specific IgG antibodies in plasma specimens were detected using ELISA as previously reported and run in triplicate 59 . Briefly, microtiter plates (Sangon Biotech) were coated overnight at 4 °C with 100 ng of each recombinant protein of MPXV, including A29L, H3L, B6R, A35R, E8L and M1R, which was expressed in E. coli expression system and purified by Ni-NTA.…”

Longitudinal Viral Shedding and Antibody Response Characteristics of Men with Acute Infection of Monkeypox Virus: A Prospective Cohort Study

“…Until recently, researchers have developed several mRNA vaccines and sub-unit vaccines based on different set of antigens 31,45,46,47,48,49,50,51 . Several surface proteins of MPXV, including M1R, E8L, H3L, A29L on the intracellular mature virion, A35R, and B6R proteins on the extracellular enveloped virion, has been found to be potential vaccine targets for MPVX 29 .…”

“…The MPXV surface proteins speci c IgG antibodies in plasma specimens were detected using Enzymelinked immunosorbent assays (ELISA) as previously reported and run in triplicate 31 . Brie y, microtiter plates (Sangon Biotech) were coated overnight at 4°C with 100 ng of each recombinant protein of MPXV, including A29L, H3L, B6R, A35R, E8L and M1R, which was expressed in E. coli expression system and puri ed by Ni-NTA.…”

Analysis of binding and authentic virus-neutralizing activities of immune sera induced by various monkeypox virus antigens

“…Vaccination is the most effective means of preventing and controlling infectious diseases, the protection rate of attenuated smallpox virus vaccines against monkeypox is about 78% 5 , it is necessary to develop vaccines with higher protection rates. Developing monkeypox vaccines based on monkeypox virus antigens is a reasonable approach, currently, multiple types of monkeypox virus protein vaccines and mRNA vaccines have been reported, these results indicate that representative monkeypox antigens, such as A29L, A35R, M1R, B6R, etc., have good immunogenicity and can induce neutralizing antibodies against the orthopox virus as immunogens 6,7 . Previous studies have mainly used the vaccinia virus as the test strain for the neutralization activity testing of sera induced by an immune response to speci c antigens of the monkeypox virus, however, the neutralization results against the vaccinia virus may deviate from those against the monkeypox virus, leading to the misleading design of novel monkeypoxspeci c vaccines.…”